pf-114
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2016 (NCT02885766)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- BCR/ABL p210 fusion proteinINHIBITOR
BCR/ABL fusion inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN1CCN(CC2=C(C=C(NC(=O)C3=CC=C(C)C(=C3)C#CC4=NN=C5C=CC=CN45)C=C2)C(F)(F)F)CC1- Mol. weight
- 532.5595 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSI8C3R768IZ ↗
Also known as
- pf-114
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02885766 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2016 | Data Matrix, LTD, Fusion Pharma LLC, OCT Clinical Trials |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Data Matrix, LTD | For profit | 1 | 0 | 1 | 2016 |
| Fusion Pharma LLC | For profit | 1 | 1 | 1 | 2016 |
| OCT Clinical Trials | For profit | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1